Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
Key Information
Due Date: January 7, 2027
Agency: U.S. Department of Health and Human Services (HHS)
Source: Federal
Funding Category:
Health & Human Services
Funding Amount: Not Specified
Funding Type: Grant, Philanthropy
Match Required: No
Contact Info:
grantsinfo@nih.gov
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Overview
This grant's primary objective is to encourage the study of Incretin Mimetics' mechanisms as they impact the risk of cancer. This research will focus on preclinical and patient-based studies looking into how substances such as GLP-1, GIP-1, or dual GLP-1/GIP-1 agents, otherwise known as incretin mimetics, influence cancer risk. The secondary aim of this grant is to attract skilled researchers who can explore the dynamic changes brought about by these agents and their impact on the risk of cancer. The research will not merely consider short-term factors such as weight loss and diabetes management. Existing data suggests that these incretin mimetics might increase the risk of certain types of obesity-related cancers while simultaneously reducing the risk of others. Clinical trials are optional but not compulsory.
Show More
Key Dates
Open Date: August 23, 2023
Application Due Date: January 7, 2027
Estimated Award Date: Not Specified
Additional Details
Eligible Activities
- Research and Development
Eligible Applicants
- State governments
- County governments
- City, village or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Private institutions of higher education
- Small businesses